Total Marrow Irradiation & Autologous Stem Cell Transplantation for Relapsed or Refractory Myeloma

  • STATUS
    Recruiting
  • End date
    Nov 21, 2025
  • participants needed
    27
  • sponsor
    Ottawa Hospital Research Institute
Updated on 21 January 2021
cancer
cell transplantation
refractory multiple myeloma

Summary

The investigators hypothesize that conformal radiation will allow the administration of higher doses of external beam radiation to marrow based malignancies than total body irradiation (TBI)without increasing the toxicity to normal tissues beyond that induced by TBI. Further,the investigators hypothesize that this will result in an improvement in disease response and disease control for patients with multiple myeloma. This is a dose escalation study of TMI with the primary objective of determining the maximum tolerated dose of TMI when followed by aHSCT in patients with relapsed or refractory multiple myeloma.

Details
Condition Multiple Myeloma, Lymphoproliferative Disorder, Lymphoproliferative disorders, multiple myeloma (mm)
Treatment Total Marrow Irradiation
Clinical Study IdentifierNCT00800059
SponsorOttawa Hospital Research Institute
Last Modified on21 January 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

A subject must meet all of the following criteria to be eligible for the study. These will be evaluated within the four weeks prior to enrolment
Subject must have primary refractory or relapsed multiple myeloma
Subject must have a measurable serum or urine monoclonal gammopathy at the time of their latest relapse
Subject must meet institutional guidelines for autologous HSCT with adequate renal, cardiac, pulmonary and hepatic function
An autologous hematopoietic stem cell graft containing more than 2.5 x 106 CD34+ cells/kg must be cryopreserved and available for transplantation
Subject must be of age more than 18 and less than 60 years
Subject must have an ECOG performance score of 0,1, or 2
Subject must have the ability to comply with the protocol visit schedule and other protocol requirements

Exclusion Criteria

A subject meeting any of the following criteria is not eligible for participation in the study
Subject with non-secretory multiple myeloma or any plasma cell disorders other that MM
Subjects that have not received previous therapy with adequate intense corticosteroids for multiple myeloma
Subjects with a severely limited life expectancy by concomitant illness, defined as a life-expectancy of less than 6 months
Subjects who have previously received radiation treatments or other neoplastic disorders
Subjects with a history of non-compliance in other studies
Pregnant or lactating female subjects
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note